Inozyme Pharma INZY Stock
Inozyme Pharma Price Chart
Inozyme Pharma INZY Financial and Trading Overview
| Inozyme Pharma stock price | 0.82 USD |
| Previous Close | 5.72 USD |
| Open | 5.69 USD |
| Bid | 0 USD x 800 |
| Ask | 0 USD x 900 |
| Day's Range | 5.62 - 6.07 USD |
| 52 Week Range | 0.99 - 7.24 USD |
| Volume | 358.84K USD |
| Avg. Volume | 714.68K USD |
| Market Cap | 255.85M USD |
| Beta (5Y Monthly) | 1.076808 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.62 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 21 USD |
INZY Valuation Measures
| Enterprise Value | 147.61M USD |
| Trailing P/E | N/A |
| Forward P/E | -3.3011363 |
| PEG Ratio (5 yr expected) | -0.21 |
| Price/Sales (ttm) | N/A |
| Price/Book (mrq) | 2.4608216 |
| Enterprise Value/Revenue | N/A |
| Enterprise Value/EBITDA | -2.126 |
Trading Information
Inozyme Pharma Stock Price History
| Beta (5Y Monthly) | 1.076808 |
| 52-Week Change | 24.94% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 7.24 USD |
| 52 Week Low | 0.99 USD |
| 50-Day Moving Average | 6 USD |
| 200-Day Moving Average | 3.26 USD |
INZY Share Statistics
| Avg. Volume (3 month) | 714.68K USD |
| Avg. Daily Volume (10-Days) | 499.22K USD |
| Shares Outstanding | 44.04M |
| Float | 16.48M |
| Short Ratio | 0.56 |
| % Held by Insiders | 1.32% |
| % Held by Institutions | 78.46% |
| Shares Short | 285.14K |
| Short % of Float | 0.64% |
| Short % of Shares Outstanding | 0.64% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | 0% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -35.00099% |
| Return on Equity (ttm) | -68.41% |
Income Statement
| Revenue (ttm) | N/A |
| Revenue Per Share (ttm) | N/A |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | N/A |
| EBITDA | -69432000 USD |
| Net Income Avi to Common (ttm) | -67581000 USD |
| Diluted EPS (ttm) | -1.39 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 130.93M USD |
| Total Cash Per Share (mrq) | 2.97 USD |
| Total Debt (mrq) | 26.66M USD |
| Total Debt/Equity (mrq) | 25.8 USD |
| Current Ratio (mrq) | 10.663 |
| Book Value Per Share (mrq) | 2.361 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -61373000 USD |
| Levered Free Cash Flow (ttm) | -35835124 USD |
Profile of Inozyme Pharma
| Country | United States |
| State | MA |
| City | Boston |
| Address | 321 Summer Street |
| ZIP | 02210 |
| Phone | 857 330 4340 |
| Website | https://www.inozyme.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 56 |
Inozyme Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases in the United States. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein, which is in Phase 1/2 clinical trials for the treatment of ENPP1 and ABCC6 deficiency, as well as for the treatment of calciphylaxis. It has a license agreement with Yale University for specified therapeutic and prophylactic products. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.
Q&A For Inozyme Pharma Stock
What is a current INZY stock price?
Inozyme Pharma INZY stock price today per share is 0.82 USD.
How to purchase Inozyme Pharma stock?
You can buy INZY shares on the NasdaqGS exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Inozyme Pharma?
The stock symbol or ticker of Inozyme Pharma is INZY.
Which industry does the Inozyme Pharma company belong to?
The Inozyme Pharma industry is Biotechnology.
How many shares does Inozyme Pharma have in circulation?
The max supply of Inozyme Pharma shares is 64.24M.
What is Inozyme Pharma Price to Earnings Ratio (PE Ratio)?
Inozyme Pharma PE Ratio is now.
What was Inozyme Pharma earnings per share over the trailing 12 months (TTM)?
Inozyme Pharma EPS is -1.62 USD over the trailing 12 months.
Which sector does the Inozyme Pharma company belong to?
The Inozyme Pharma sector is Healthcare.
Inozyme Pharma INZY included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| NASDAQ Composite IXIC | 15587.79 USD — |
-5.82
|
9.14B USD — | 15575.68 USD — | 16128.16 USD — | — - | 9.14B USD — |
| NASDAQ Global Select Market Com NQGS | 7625.89 USD — |
-5.84
|
— — | 7621.56 USD — | 7894.21 USD — | — - | — — |
| NASDAQ HealthCare IXHC | 869.8 USD — |
-5.51
|
— — | 868.74 USD — | 900.72 USD — | — - | — — |
- {{ link.label }} {{link}}